The nano ap­proach Of medicines

BioSpectrum (Asia) - - Bio Content - Dr Man­beena Chawla man­beena.chawla@mmac­tiv.com

In­crease in adop­tion of novel nanomedicines prod­ucts drives the mar­ket growth in In­dia. More­over, in­crease in the number of play­ers and high adop­tion of in­no­va­tive tech­nolo­gies fur­ther fuel the mar­ket growth. In ad­di­tion, ro­bust govern­ment ini­tia­tive to­ward im­prove­ment of health­care fa­cil­i­ties through in­sur­ance schemes is an­tic­i­pated to pro­vide lu­cra­tive growth op­por­tu­ni­ties in the coun­try. The nanomedicines mar­ket in In­dia is ex­pected to grow at the high­est CAGR of 13.4% from 2016 to 2023.

Ge­o­graph­i­cally, the mar­ket for nanomedicine is seg­mented into North Amer­ica, Eu­rope, Asia-Pa­cific, Mid­dle East & Africa, and Latin Amer­ica. Cur­rently, North Amer­ica ac­counts for the largest mar­ket share.

The Asia-Pa­cific re­gion is ex­pected to grow at the high­est CAGR dur­ing the fore­cast pe­riod of 2018-2023, ow­ing to the im­prov­ing re­search in­fra­struc­ture in the re­gion, im­proved pur­chas­ing power of pa­tients, the rapid in­crease in ge­ri­atric pop­u­la­tion, and ris­ing aware­ness re­gard­ing health­care. China and In­dia are to be fore­seen as the grow­ing nanomedicine mar­kets in Asia.

The global nanomedicine mar­ket ac­counted for $111.9 bil­lion in 2016, and is an­tic­i­pated to reach $261.1 bil­lion by 2023,

reg­is­ter­ing a CAGR of 12.6 per cent from 2017 to 2023, ac­cord­ing to a new re­port pub­lished by Al­lied Mar­ket Re­search.

A new re­port by Grand View Re­search, Inc. ob­served that the global nanomedicine mar­ket is an­tic­i­pated to reach $ 350.8 bil­lion by 2025. De­vel­op­ment of novel nan­otech­nol­ogy-based drugs and ther­a­pies is driven by the need to de­velop ther­a­pies that have fewer side ef­fects and that are more cost-ef­fec­tive than tra­di­tional ther­a­pies, in par­tic­u­lar for cancer.

Ap­pli­ca­tion of nan­otech­nol­ogy-based con­trast reagents for di­ag­no­sis and mon­i­tor­ing of the ef­fects of drugs on an un­prece­dented short timescale is also at­tribu­tive drive growth in the com­ing years. Ad­di­tion­ally, de­mand for biodegrad­able im­plants with longer life­times that en­able tis­sue restora­tion is an­tic­i­pated to in­flu­ence de­mand.

As per the World Health Or­gan­i­sa­tion (WHO) fact­sheet, cancer is found to be one of the ma­jor causes of mor­tal­ity and mor­bid­ity world­wide, with ap­prox­i­mately 14 mil­lion new cases in 2012 and 8.2 mil­lion cancer-re­lated deaths. Thus, de­mand for nanomedicine in or­der to curb such high in­ci­dence rate is ex­pected to boost mar­ket progress dur­ing the fore­cast pe­riod.

So­lu­tions such as nanofor­mu­la­tions with trig­gered re­lease for tailor-made phar­ma­coki­net­ics, nanopar­ti­cles for lo­cal con­trol of tu­mor in com­bi­na­tion with ra­dio­ther­apy, and func­tion­al­ized nanopar­ti­cles for tar­geted in-vivo ac­ti­va­tion of stem cell pro­duc­tion are an­tic­i­pated to drive R&D, con­se­quently re­sult­ing in rev­enue gen­er­a­tion in the com­ing years.

Bio­phar­ma­ceu­ti­cal and med­i­cal de­vices com­pa­nies are ac­tively en­gaged in de­vel­op­ment of novel prod­ucts as demon­strated by the in­creas­ingly grow­ing part­ner­ships be­tween lead­ing en­ter­prises and nanomedicine star­tups. Nan­otech­nol­ogy is one of the most promis­ing tech­nolo­gies in the 21st cen­tury. The nanomedicine branch of­fers an im­pres­sive solution for var­i­ous life threat­en­ing dis­eases such as cancer, Parkinson, Alzheimer, di­a­betes, or­tho­pe­dic prob­lems, dis­eases re­lated to blood, lungs, neu­ro­log­i­cal, and car­dio­vas­cu­lar sys­tem.

In 2007, in­vest­ment in nan­otech­nol­ogy by ven­ture cap­i­tal­ists (VCs) was $702 mil­lion, across 61 deals. Of these, 27 per cent went to health­care and life sci­ence. Two years later, the nan­otech­nol­ogy mar­ket cap­tured $792 mil­lion in VC in­vest­ment, with the largest share (51 per cent) go­ing to health­care and life sciences. This dou­bling of the funds in­vested in health­care in such a short pe­riod demon­strates in­vestor in­ter­est in nanomedicine.

Around the same time in 2007, the Govern­ment of In­dia ap­proved the launch of a Mis­sion on Nano Sci­ence and Tech­nol­ogy (Nano Mis­sion) with an al­lo­ca­tion of Rs 1000 crore for 5 years. Rec­og­niz­ing the suc­cess of Nano Mis­sion, the Union Cabi­net ac­corded ap­proval for con­tin­u­a­tion of the Nano Mis­sion in its Phase-II dur­ing the 12th Plan pe­riod with an al­lo­ca­tion of Rs 650 crore.

Nano Mis­sion is cur­rently be­ing chaired by Pro­fes­sor CNR Rao, FRS, Na­tional Re­search Pro­fes­sor and Honorary President & Li­nus Paul­ing Re­search Pro­fes­sor, Jawa­har­lal Nehru Cen­tre for Ad­vanced Sci­en­tific Re­search, Ben­galuru. “Though In­dia ranks third in terms of pub­li­ca­tions on Nano Sciences, it was be­hind sev­eral na­tions in terms of us­ing it in the field of medicine. The coun­try needs to progress more in the field of nanomedicine. It is a fast emerg­ing area with enor­mous prom­ise of tack­ling hith­erto-com­plex and tough dis­eases like can­cers, neu­rode­gen­er­a­tive dis­or­ders and in­fec­tions”, he pointed out while at­tend­ing the 9th edi­tion of Ben­galuru In­dia Nano event re­cently.

As a part of the ef­forts to­wards fos­ter­ing a business en­vi­ron­ment for the de­vel­op­ment of Nanoscience and

Nan­otech­nol­ogy In­dus­try in In­dia, Ben­galuru In­dia Nano event is be­ing or­ga­nized ev­ery year since its in­cep­tion in 2007.

At the lat­est edi­tion of the Ben­galuru In­dia Nano event in De­cem­ber 2017, a sep­a­rate ses­sion on nanomedicine was con­ducted in or­der to dis­cuss the lat­est re­search be­ing car­ried out at dif­fer­ent in­sti­tutes all over In­dia. “Our team is work­ing on a tech­nique based on gold nano-struc­tures that would of­fer cancer treat­ment at just Rs 10,000. The Phase 1 tri­als are com­pleted and we are pre­par­ing for Phase 2 test­ing of the pro­ce­dure”, dis­cussed Prof Ro­hit Sri­vas­tava, IITBom­bay, while giv­ing out a pre­sen­ta­tion at the event.

“The global nanomedicine mar­ket is driven by emerg­ing in­no­va­tive tech­nolo­gies for drug de­liv­ery, ad­van­tages of nanomedicine in var­i­ous health­care ap­pli­ca­tions, rise in govern­ment sup­port and fund­ing, and growth in need for safe and cost-ef­fec­tive ther­a­pies”, ex­plained Prof Ashok K Gan­guli, Direc­tor, In­sti­tute of Nano Sci­ence and Tech­nol­ogy, Mo­hali.

The In­dian So­ci­ety of Nano Medicine (ISNM) was launched in 2016 in or­der to bring sev­eral In­dian nano tech­nol­ogy re­searchers to­gether and use it for slash­ing high cost of medicines, pro­vide cus­tomised treat­ment and im­prove di­ag­nos­tics.

“This plat­form will give mem­bers an op­por­tu­nity to closely in­ter­act with peers in the field of nanomedicine with par­tic­u­lar em­pha­sis on the in­ter­dis­ci­pli­nary na­ture of the con­tacts be­tween in­no­va­tors and physi­cians fo­cus­ing on clin­i­cal ap­pli­ca­tion. Apart from pro­vid­ing tar­geted de­liv­ery, nano drugs will help in low­er­ing the cost as dosage will re­duce from mil­ligrams to nanograms with less side ef­fects. The ISNM will also see col­lab­o­ra­tions in fu­ture with Amer­i­can So­ci­ety of Nano Medicine and sim­i­lar so­ci­eties from other coun­tries as well”, shared Amit Dinda, Sec­re­tary of ISNM.

Three teams from BRICS coun­tries, in­clud­ing Rus­sia and In­dia, have re­cently planned to em­bark on a pro­ject that uses the ben­e­fits of nanomedicine to si­mul­ta­ne­ously bun­dle both di­ag­nos­tics and ther­apy into one pack­age for treat­ing cancer.

“Nan­otech­nol­ogy has come a long way in the last five years and now nanomedicine, a mar­riage of nan­otech­nol­ogy and medicine, is tak­ing its place in the fight against un­met dis­eases. With the prom­ise of med­i­cal ap­pli­ca­tions such as tar­geted cancer treat­ments, mi­cro­scopic sen­sors and even de­vices that mimic hu­man or­gans in the fu­ture, en­thu­si­asm for the field is backed by se­ri­ous re­search and de­vel­op­ment fund­ing from govern­ment and in­dus­try”, high­lighted Prof Satya­jit Mayor, Direc­tor, Na­tional Cen­tre for Bi­o­log­i­cal Sciences (NCBS), Ben­galuru.

The in­vest­ment in the nanomedicine mar­ket is set to in­crease. New ap­pli­ca­tions have demon­strated its value, and the re­sult­ing ex­pan­sion of po­ten­tial mar­kets makes the risk more ap­peal­ing.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.